Dr. Harper discusses results from head-to-head studies comparing new and existing oral rosacea treatments and navigating the difficulties of treating neurogenic rosacea.
Dr. Lio discusses the nuances of approaching patient questions and misconceptions around dietary modifications and restrictions for atopic dermatitis.
PLAY
Emmy Graber, MD: New Efficacy Evidence for Acne and Rosacea Devices
Dr. Graber discusses new evidence supporting the use of 1726nm lasers for the treatment of inflammatory and non-inflammatory acne, as well as pulsed-dye laser and...
PLAY
Steve Daveluy, MD: Using Cryoinsufflation in Patients with Hidradenitis Suppurativa
Dr. Daveluy provides tips and guidance for using cryoinsufflation in the treatment of HS.
PLAY
Christopher Bunick, MD, PhD: Clearing Up Questions Around Benzene in Benzoyl Peroxide Products
Dr. Bunick explores the discussion on benzene in benzoyl peroxide (BPO) products, including questions around ensuring products are meeting FDA regulations, what dermatologists can do...
PLAY
Jennifer Hsiao, MD: Recalcitrant Hidradenitis Suppurativa—What to do Next?
Dr. Jennifer Hsiao shares emerging strategies for treating recalcitrant hidradenitis suppurativa when standard therapies fail. Topics Covered: Management of treatment-resistant HS Emerging therapies and clinical...
PLAY
Christopher Bunick, MD, PhD: Antibiotic Update for Acne and Rosacea
Dr. Bunick provides a comprehensive update on using antibiotics for the treatment of acne and rosacea, including influences on gut health, antibiotic resistance, and efficacy...
PLAYDr. Jennifer Hsiao explores dual biologic therapy as a potential strategy for managing complex, treatment-resistant cases of hidradenitis suppurativa. Topics Covered: Dual biologic use in
Dr. Neal Bhatia reviews promising topical therapies in development, highlighting new mechanisms and formulations shaping the future of dermatologic care. Topics Covered: Emerging topical therapies
Dr. Liu discusses new and emerging topical therapies for psoriasis and the continued value of topical therapies in psoriasis treatment.
Dr. Andrea Murina discusses how oral therapies can serve as an effective entry point to systemic treatment for patients with psoriasis. Topics Covered: Role of
Dr. Mark Lebwohl outlines key considerations for treating psoriasis in elderly patients, including comorbidities, cancer risk, and treatment affordability. Topics Covered: Psoriasis management in older
Dr. Daveluy discusses an exciting new project to uncover insights into HS disease patterns through analysis with artificial intelligence.
Dr. Elbuluk discusses unique considerations pertaining to inflammatory skin diseases in patients with skin of color.
Dr. Khattri discusses emerging psoriatic arthritis treatments on the horizon, including deucravacitinib, zasocitinib, and icotrokinra.
Dr. James Song reviews how IL-17 inhibitors can be especially effective in treating psoriatic arthritis, special-site psoriasis, and biologic-experienced patients. Topics Covered: IL-17 inhibitors in
Dr. Cohen discusses the best biologics for treating psoriasis of the scalp, intertriginous areas, genitals, nails, and palms and soles of the feet.
Dr. Bhatia reviews exciting new developments in dermatology technology, including a full-body dermoscopic robot, autologous cell transplants for wound healing, and stem cell banking for
The AAD © Brand and Content are created by the American Academy of Dermatology “All rights reserved.” Any reproduction or republication is strictly prohibited without prior authorization.
The content of the 2025 AAD Innovation Academy Meeting (the “Content”) is copyrighted by the American Academy of Dermatology (“AAD”). The Works, JCADTV Coverage from the 2025 AAD Innovation Academy Meeting, are made up of coverage interviews and summaries and are created from the Content of the AAD under a license between the AAD and Matrix Medical Communications (“MATRIX MEDICAL COMMUNICATIONS”), and MATRIX MEDICAL COMMUNICATIONS is solely responsible for their content. The license of any content by the AAD does not constitute or imply endorsement of any company or its goods, services, or written work products, and the AAD is not responsible for any errors or omissions in the translation or reproduction of the content.
